Colo.–(BUSINESS WIRE)–Biodesix, Inc., a fully integrated molecular diagnostics
company dedicated to personalizing medicine, today announced the issuance of
three additional patents. The U.S. Patent & Trademark Office (PTO) granted
two new patents which provide intellectual property protection for methods
relating to the Companys products and technology. In addition, the European Patent Office granted
to Biodesix a patent providing coverage for the Companys product VeriStrat®, for the selection of patients for drug therapy.
VeriStrat is a serum proteomic test currently available in the United States
to help physicians guide therapy for patients with advanced lung cancer.
European patent number 2,247,954 is the counterpart to U.S. patent
number 7,867,775 and covers the use of VeriStrat for selection of head and neck
cancer patients for treatment with targeted drugs. U. S. patent number
8,024,282 (â€˜282) provides additional intellectual property protection for the
methods used with VeriStrat which are also related to Biodesix underlying core
ProTS® technology. Specifically, the â€˜282 patent supports the Companys methods
for the reliable and reproducible classification of samples in clinical
diagnostics using computer systems configured as probabilistic classifiers.
Related U.S. patent 7,906,342 covers Biodesix methods for using mass
spectrometry of patient samples to monitor cancer patients being treated with
drugs targeting the epidermal growth factor receptor (EGFR) pathway for response
or non-responsiveness to the treatment. Biodesix also received notice from the
PTO that two additional patent applications covering the use of VeriStrat for
monitoring of head and neck, as well as colorectal cancer patients being
treated with drugs targeting the EGFR pathway have been allowed; these patents
are expected to issue early in the first quarter of 2012.
Drug therapies targeting the EGFR pathway and related
molecular targets play an increasingly important role in cancer therapy.
Identifying patients likely to benefit from this class of drugs is key to
improving overall patient outcomes.
“The expansion of our patent estate is an integral part of
our global strategy to protect VeriStrat and our technology platform,”
commented David Brunel, Biodesix CEO. “This protection strengthens our
commercial position as a leading provider of diagnostics to personalize
medicine for oncology patients.”
Biodesix is a fully integrated molecular diagnostics company advancing the
development of products for personalized medicine. Biodesix provides physicians
with tools for earlier disease detection, more accurate diagnosis, and better
therapeutic guidance. In 2009, Biodesix launched VeriStrat®, a serum proteomic
test that helps physicians guide treatment for patients with non-small cell
lung cancer. VeriStrat is based on ProTS®, proprietary technology which
harnesses the power of mass spectrometry and enables the discovery of specific
molecular profiles that characterize a patients condition or likely outcome in
response to therapy. The ProTS® platform has broad application and provides the
foundation for collaborations with leading researchers as well as partnerships
with biotechnology and pharmaceutical companies seeking to develop companion diagnostics
and improve the targeting of their therapies. For more information about
Biodesix, please visit the Companys website at www.Biodesix.com.
Posted by Sean Fenske, Editor-in-Chief, MDT